According to the study, the global HIV diagnosis market is likely to grow significantly during the forecast period, due to rising prevalence of HIV/AIDS, increasing awareness with respect to blood donations and blood transfusions, and advantageous features of point of care instruments and kits are some of the key drivers for the global market growth. In addition, rising healthcare expenditure leading to improvement in healthcare infrastructure further contributes to the growth of the overall market. High cost of automated procedure and stringent regulatory requirements are some of the key factors restraining the global market growth.
As per the findings of the research, based on products, consumable is the largest product category, in the global market. Antibody test has been the largely performed test of the global market, followed by viral load, CD4, early infant diagnosis and viral identification. Diagnostic laboratories have been the largest end user of HIV diagnosis, followed by hospitals, research institutes and others.
Geographically, North America has been the largest market for HIV diagnosis, with the U.S. being the largest contributor to the regional market. Increasing prevalence of HIV/AIDS and advantageous features of point of care instruments and kits has been driving the growth of the North American market. In Europe, the U.K. has been the largest contributor to the market for HIV diagnosis, followed by Germany and France. The market is expected to witness the fastest growth in Asia-Pacific, during 2017 – 2023, owing to increasing cases of HIV rising healthcare expenditure and increasing blood transfusion.
Some of the key players in the global HIV diagnosis market include Siemens AG, Hoffman La Roche Ltd., Danaher Corporation, Abbott Laboratories, Ltd., Thermo-Fisher Scientific Inc., Merck KGaA, Becton, Dickinson & Company, Alere Inc., Bio-Rad Laboratories and Hologic Inc.
News Courtesy: P&S Market Research